What is Tango Therapeutics?
Tango Therapeutics operates at the intersection of genomics and drug discovery, specializing in precision oncology. The company utilizes a proprietary platform to identify and validate novel targets that are synthetically lethal to cancer cells, effectively creating a roadmap for highly specific therapeutic interventions. By focusing on genetically defined patient populations, Tango Therapeutics minimizes off-target effects while maximizing efficacy, a core differentiator in the competitive biotechnology landscape. Their market position is bolstered by a commitment to rigorous scientific validation and a strategic focus on high-impact oncology indications.
How much funding has Tango Therapeutics raised?
Tango Therapeutics has raised a total of $455M across 4 funding rounds:
Private Equity
$50M
Other Financing Round
$165M
Stock/Share Issuance
$225M
Stock/Share Issuance
$15M
Private Equity (2020): $50M with participation from Casdin Capital , LLC, Cormorant Asset Management , LLC, and Boxer Capital , LLC
Other Financing Round (2020): $165M, investors not publicly disclosed
Stock/Share Issuance (2025): $225M supported by Woodline Partners, Balyasny Asset Management, Farallon, and TCG Crossover
Stock/Share Issuance (2025): $15M, investors not publicly disclosed
Key Investors in Tango Therapeutics
Woodline Partners
San Francisco-based Woodline Partners LP is an investment firm implementing a market neutral equity strategy, focused on the global Healthcare and Technology sectors.
Balyasny Asset Management
Balyasny Asset Management is a global investment firm focused on delivering consistent returns for institutional investors through deep research and disciplined risk management.
Farallon
Farallon is an investment management company that manages discretionary equity capital from institutional investors such as university endowments, foundations, and pension plans.
What's next for Tango Therapeutics?
With the recent influx of capital, Tango Therapeutics is well-positioned to scale its research and development operations. The strategic focus will likely shift toward expanding clinical trial capacity and deepening the pipeline of novel therapeutics. As the company matures, the emphasis will remain on translating genetic discoveries into tangible clinical outcomes, potentially setting the stage for future commercialization efforts or strategic partnerships with larger pharmaceutical entities. The firm's ability to maintain its scientific edge while navigating the complexities of clinical development will be the primary determinant of its long-term value creation for stakeholders.
See full Tango Therapeutics company page
